CriticalAntidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative×SNRI (serotonin-norepinephrine reuptake inhibitor)
Updated · Methodology
Mechanism
Venlafaxine and its main metabolite, O-desmethylvenlafaxine, inhibit the reuptake of serotonin and noradrenaline, but venlafaxine does not inhibit monoamine oxidase (MAO) (venlafaxine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Tranylcypromine irreversibly and non-selectively inhibits MAO A and B and stops the enzyme from breaking down serotonin, noradrenaline and dopamine (tranylcypromine SmPC, AEMPS). Venlafaxine can cause serotonin syndrome on its own, and the risk is higher with drugs that impair serotonin breakdown, such as MAO inhibitors (venlafaxine SmPC, AEMPS). Full MAO activity returns only 3–5 days after the last dose of tranylcypromine (tranylcypromine SmPC, AEMPS). According to the US label, MAO inhibition may persist for up to 10 days (tranylcypromine label, US Food and Drug Administration, FDA). The half-lives of venlafaxine and O-desmethylvenlafaxine are about 5 and 11 hours (venlafaxine SmPC, AEMPS).
Symptoms
Serotonin syndrome with tranylcypromine and venlafaxine can be severe and life-threatening (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The venlafaxine SmPC reports tremor, myoclonus, sweating, nausea, vomiting, flushing, dizziness, high body temperature with features resembling neuroleptic malignant syndrome, seizures and death in people who had recently stopped a monoamine oxidase inhibitor and started venlafaxine, or the other way round (venlafaxine SmPC, AEMPS). Serotonin syndrome presents with mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, fever), neuromuscular abnormalities (overactive reflexes, poor coordination), nausea, vomiting or diarrhoea (venlafaxine SmPC, AEMPS). The US tranylcypromine label reports fatal cases, including in people treated with tranylcypromine. It also states that when tranylcypromine interacted with serotonin and noradrenaline reuptake inhibitors, the picture sometimes resembled neuroleptic malignant syndrome (tranylcypromine label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. The Spanish tranylcypromine summary of product characteristics (SmPC) names venlafaxine among the drugs that must not be given with tranylcypromine. The Spanish venlafaxine SmPC contraindicates irreversible monoamine oxidase (MAO) inhibitors, and according to its own SmPC tranylcypromine belongs to this group (tranylcypromine and venlafaxine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The US tranylcypromine label lists serotonin and noradrenaline reuptake inhibitors among contraindicated products, and the US venlafaxine label contraindicates MAO inhibitors (tranylcypromine and venlafaxine labels, US Food and Drug Administration, FDA). Start venlafaxine at least 14 days after stopping tranylcypromine (venlafaxine SmPC, AEMPS, and FDA label; tranylcypromine SmPC, AEMPS). Stop venlafaxine at least 7 days before starting tranylcypromine (venlafaxine SmPC, AEMPS, and FDA label). For a switch from another antidepressant, the Spanish tranylcypromine SmPC recommends a drug-free interval of about 5 half-lives of the previous drug and its active metabolites (tranylcypromine SmPC, AEMPS). The US label gives 4–5 half-lives (tranylcypromine FDA label). If serotonin syndrome develops, stop venlafaxine, tranylcypromine and any other serotonergic drug at once and start supportive symptomatic treatment (venlafaxine and tranylcypromine FDA labels). Treat severe serotonin syndrome caused by an interaction as tranylcypromine poisoning: in intensive care, with close monitoring of pulse, blood pressure, breathing and temperature, and with mechanical ventilation available. For severe agitation or marked muscle rigidity, the SmPC recommends benzodiazepines, and oral cyproheptadine may be tried to block serotonin receptors. At a body temperature of 40 °C or higher, start active cooling at once (tranylcypromine SmPC, AEMPS, overdose section).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Effexor XR (venlafaxine) prescribing information (2023)– FDA label, Viatris Specialty LLC, DailyMed setid c848a5d8-ba94-4c84-80e3-0bf35fb8e32e, revised 08/2023, sections 5.4, 7 and 17
- AEMPS: Ficha técnica: Venlafaxina (nº registro 67542), sección 4.3 (2024)– AEMPS, CIMA, nº registro 67542, revisión 03/2024, sección 4.3
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.3 (2026)– AEMPS, CIMA, nº registro 88524, revisión 08/2026, sección 4.3
- FDA: Parnate (tranylcypromine) prescribing information (2025)– FDA, DailyMed, Advanz Pharma, setid b72d8187-dfcc-4ea0-b5e9-c0be95b69a27, revised 07/2025, sections 4.1, 5.3, 5.9 and 7.1
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.5 (2026)– AEMPS, CIMA, nº registro 88524 (Tranilcipromina Aristo 20 mg comprimidos recubiertos con película; autorizado, no comercializado), revisión 08/2026 (texto revisado 04/2026), secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.1
- AEMPS: Ficha técnica: Vandral Retard 75 mg (venlafaxina, nº registro 62401), sección 4.3 (2024)– AEMPS, CIMA, nº registro 62401 (Vandral Retard 75 mg cápsulas duras de liberación prolongada, Viatris), revisión 05/2024, secciones 4.3, 4.4, 4.5, 5.1 y 5.2